Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-138/BCMA/19/more for Relapsed/Refractory Multiple Myeloma
NCT03196414Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2016
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CART-138 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Grade 3 to 5 Cytokine Release Syndrome at 12 months. Started Sep 2016; status: recruiting.
02
Drugs
CART-138
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03196414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196414.